Share on StockTwits

MacroGenics (NASDAQ:MGNX) VP Jon Marc Wigginton unloaded 5,000 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $20.52, for a total transaction of $102,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on MGNX. Analysts at Oppenheimer initiated coverage on shares of MacroGenics in a research note on Thursday, July 10th. They set an “outperform” rating and a $48.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of MacroGenics from $28.00 to $30.00 in a research note on Thursday, June 19th. Finally, analysts at Roth Capital initiated coverage on shares of MacroGenics in a research note on Monday, June 9th. They set a “buy” rating and a $28.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $50.50.

MacroGenics (NASDAQ:MGNX) traded up 4.09% during mid-day trading on Thursday, hitting $21.005. The stock had a trading volume of 328,517 shares. MacroGenics has a one year low of $17.96 and a one year high of $41.00. The stock’s 50-day moving average is $20.23 and its 200-day moving average is $24.80. The company’s market cap is $582.6 million.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.29) by $0.15. Analysts expect that MacroGenics will post $-1.39 EPS for the current fiscal year.

MacroGenics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.